Related Experiment Video
Updated: May 12, 2026
Lung Rapid Recovery Procurement Combined with Abdominal Normothermic Regional Perfusion in Controlled Donation after Circulatory Death
Published on: August 15, 2022
Survival benefit of lung transplant for cystic fibrosis since lung allocation score implementation
Gabriel Thabut1, Jason D Christie, Hervé Mal
1Service de Pneumologie B et Transplantation Pulmonaire, Université Paris 7 Denis Diderot, Hôpital Bichat, Paris, France. g.thabut@gmail.com
Rationale:
The survival benefit of lung transplantation (LT) in adult patients with cystic fibrosis (CF) is debated.
Objectives:
We sought to assess the survival benefit of LT in adult patients with CF.
Methods:
We used data from the United Network for Organ Sharing Registry to identify adult patients with CF on a wait list for LT in the United States between 2005 and 2009. Survival times while on the wait list and after LT were modeled by use of a Cox model that incorporated transplantation status as a time-dependent covariate. Evolution in lung allocation score (LAS) while on the wait list was used as a surrogate for disease severity. We fitted a model for the joint distribution of survival and longitudinal disease process (LAS over time).
Measurements And Main Results:
A total of 704 adult patients with CF were registered on a wait list during the study period. The cumulative incidence of LT was 39.3% (95% confidence interval, 35.6-42.9%) at 3 months and 64.7% (61.0-68.4%) at 12 months, whereas the incidence of death while on the wait list at the same times was 8.5% (6.4-10.6%) and 12.9% (10.3-15.5%), respectively. Survival after LT was 96.5% (94.7-98.2%) at 3 months; 88.4% (85.1-91.8%) at 12 months; and 67.8% (59.9-76.8%) at 3 years. LT conferred a 69% reduction in the instantaneous risk of death (51-80%). The interaction between LAS and LT was significant: the higher the LAS, the greater the survival benefit of LT (P < 0.001).
Conclusions:
LT confers a survival benefit for adult patients with CF.
